Top Markets
#1 Islamic Coin Islamic Coin +151.45%
#2 DOVU DOVU +49.92%
#3 Velvet Velvet +43.90%
#4 Black Phoenix Black Phoenix +34.98%
#5 Palladium Network Palladium Network +21.70%
#6 Fake World Assets Fake World Assets +19.35%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.99%
#8 DoubleZero DoubleZero +18.67%
#9 Akedo Akedo +18.04%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +13.01%
Coin of the day
Islamic Coin Islamic Coin
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Rang în acțiuni #39944
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Preț acțiune
$0.00366968
Ultima sincronizare: 2024-07-23
Capitalizare de piață
$291.42K
Schimbare (1 zi)
-0.81%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Bioasis Technologies Inc. (BTI)

Categorie

Healthcare
Câștiguri pentru Bioasis Technologies Inc. (BTI)
Câștiguri în 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Bioasis Technologies Inc., câștigurile actuale ale companiei sunt 0. În anul 2026, compania a înregistrat un câștig de 0, egal cu câștigului din 2026, care a fost de 0. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Bioasis Technologies Inc. din 2026 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE